In the subgroup analysis by breast cancer subtypes, significantly better DFS and DMFS were shown in luminal A, luminal B, and HER2 subtypes in the later period (Figs 2 and S1), and the difference was more dramatic in subtypes with HER2(+). This evidence concerns the gene ERBB2 and breast carcinoma.